Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer
Cancer Epidemiology, Biomarkers & Prevention, 11/16/2011
Wolpin BM et al. – Among participants in five large prospective cohorts, higher plasma levels of 25(OH)D were associated with a lower risk for pancreatic cancer. Low circulating 25(OH)D may predispose individuals to the development of pancreatic cancer.
Methods- To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D) were associated with risk of pancreatic cancer, the authors performed a nested case-control study of 451 cases and 1167 controls from five cohorts through 2008.
- Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH)D.
- Mean plasma 25(OH)D was lower in cases versus controls (61.3 vs. 64.5nmol/L, P=0.005).
- In logistic regression models, plasma 25(OH)D was inversely associated with odds of pancreatic cancer.
- Participants in quintiles two through five had multivariable-adjusted odds ratios (OR [95% confidence intervals]) of 0.79 (0.56-1.10), 0.75 (0.53-1.06), 0.68 (0.48-0.97), and 0.67 (0.46-0.97); P-trend=0.03), respectively, compared to the bottom quintile.
- Compared to those with insufficient levels (25[OH]D<50nmol/L), ORs were 0.75 (0.58-0.98) for subjects with relative insufficiency (25[OH]D 50-<75nmol/L) and 0.71 (0.52-0.97) for those with sufficient levels (25[OH]D≥75 nmol/L).
- No increased risk was noted in subjects with 25(OH)D ≥100nmol/L, as suggested in a prior study.
- In subgroup analyses, ORs for the top versus bottom quartile of 25(OH)D were 0.72 (0.48-1.08) for women, 0.73 (0.40-1.31) for men, and 0.73 (0.51-1.03) for Whites.
